Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study

被引:25
作者
Bricheux, A. [1 ]
Lenggenhager, L. [2 ,3 ]
Hughes, S. [4 ]
Karmime, A. [4 ]
Lescuyer, P. [4 ]
Huttner, A. [2 ,3 ]
机构
[1] Univ Geneva, Fac Med, Geneva, Switzerland
[2] Geneva Univ Hosp, Div Infect Dis, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland
[3] Fac Med, Geneva, Switzerland
[4] Geneva Univ Hosp, Toxicol & Therapeut Drug Monitoring Lab, Geneva, Switzerland
关键词
Clinical failure; Imipenem; Plasma concentrations; Therapeutic drug monitoring; Therapeutic range; Toxicity; CRITICALLY-ILL; ANTIBIOTICS; PHARMACOKINETICS;
D O I
10.1016/j.cmi.2018.11.020
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Therapeutic drug monitoring (TDM) of beta-lactam antibiotics is increasingly employed to ensure adequate antibiotic exposure and slow emergence of resistance. Imipenem's therapeutic range has not been defined; we report plasma concentrations and clinical outcomes of patients receiving imipenem for bacterial infections. Methods: All hospitalized adult patients undergoing imipenem TDM during therapy for suspected or confirmed bacterial infections between 1 January 2013 and 28 February 2017 were included in this single-centre retrospective cohort. The primary outcome was incidence of clinical toxicity; secondary outcomes included incidence of clinical failure and median imipenem concentrations in those with and without toxicity and/or failure. Total imipenem concentrations were measured via high-performance liquid chromatography with ultraviolet detection. Results: A total of 403 imipenem levels were drawn from 300 patients. Fifteen (5%) patients experienced an adverse event considered at least possibly related to imipenem. Eighty-eight (29%) patients had clinical failure; augmented renal clearance appeared to emerge as a protective factor against failure (OR 0.42; 95% CI 0.20-0.89). Median first-measure trough concentration was 3.2 mg/L (IQR 1.7-6.5). Patients with suspected toxicity did not have higher concentrations. Patients whose dose was not increased after a trough level < 2 mg/L was returned trended towards increased clinical failure (3/28 (11%) vs. 12/63 (19%)), though the difference was not statistically significant. Conclusions: Toxicity was rare and clinical failure frequent in this cohort of patients whose imipenem concentrations were generally low and occasionally undetectable. Larger trials are needed to define optimal imipenem exposure. (c) 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:383.e1 / 383.e4
页数:4
相关论文
共 12 条
[1]   Imipenem levels are not predictable in the critically ill patient [J].
Belzberg, H ;
Zhu, J ;
Cornwell, EE ;
Murray, JA ;
Sava, J ;
Salim, A ;
Velmahos, GC ;
Gill, MA .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2004, 56 (01) :111-117
[2]   Prospective determination of plasma imipenem concentrations in critically ill children [J].
Giannoni, Eric ;
Moreillon, Philippe ;
Cotting, Jacques ;
Moessinger, Adrien ;
Bille, Jacques ;
Decosterd, Laurent ;
Zanetti, Giorgio ;
Majcherczyk, Paul ;
Bugnon, Denis .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) :2563-2568
[3]   Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams [J].
Goncalves-Pereira, Joao ;
Povoa, Pedro .
CRITICAL CARE, 2011, 15 (05)
[4]   Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? [J].
Huttner, Angela ;
Harbarth, Stephan ;
Hope, William W. ;
Lipman, Jeffrey ;
Roberts, Jason A. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (12) :3178-3183
[5]   Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study [J].
Huttner, Angela ;
Von Dach, Elodie ;
Renzoni, Adriana ;
Huttner, Benedikt D. ;
Affaticati, Mathieu ;
Pagani, Leonardo ;
Daali, Yousef ;
Pugin, Jerome ;
Karmime, Abderrahim ;
Fathi, Marc ;
Lew, Daniel ;
Harbarth, Stephan .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (04) :385-392
[6]   Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study [J].
Huwyler, T. ;
Lenggenhager, L. ;
Abbas, M. ;
Lorenzini, K. Ing ;
Hughes, S. ;
Huttner, B. ;
Karmime, A. ;
Uckay, I. ;
von Dach, E. ;
Lescuyer, P. ;
Harbarth, S. ;
Huttner, A. .
CLINICAL MICROBIOLOGY AND INFECTION, 2017, 23 (07) :454-459
[7]   Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships [J].
Imani, Sahand ;
Buscher, Hergen ;
Marriott, Debbie ;
Gentili, Sheridan ;
Sandaradura, Indy .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (10) :2891-2897
[8]   IMIPENEM PHARMACOKINETICS AND BODY-FLUID CONCENTRATIONS IN PATIENTS RECEIVING HIGH-DOSE TREATMENT FOR SERIOUS INFECTIONS [J].
MACGREGOR, RR ;
GIBSON, GA ;
BLAND, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (02) :188-192
[9]   Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections? [J].
Muller, Anouk E. ;
Huttner, Benedikt ;
Huttner, Angela .
DRUGS, 2018, 78 (04) :439-451
[10]   What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance [J].
Udy, Andrew A. ;
Roberts, Jason A. ;
De Waele, Jan J. ;
Paterson, David L. ;
Lipman, Jeffrey .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (06) :455-457